Opinion

Video

Lower-Risk MDS: How Do Practice Patterns Compare Worldwide?

Author(s):

Uwe Platzbecker, MD,Rami Komrokji, MD

Comprehensive insights on the differences and similarities in treatment algorithms for physicians treating patients with MDS in and outside the United States. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Related Videos
2 expert is featured in this series.
3 experts are featured in this series.
2 experts in this video
2 experts in this video
Ashkan Emadi, MD, PhD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Related Content
OncLive’s December Roundup of Key FDA Approvals in Oncology
December 30th 2024

OncLive’s December Roundup of Key FDA Approvals in Oncology

Onyee Chan, MD, hematologist/oncologist, Moffitt Cancer Center Magnolia Campus; Bradley D. Hunter, MD, medical director, Oncology, director, Immune Effector Cell Therapy, Intermountain Healthcare
December 24th 2024

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

Joseph A. Sparano, MD, FACP
December 23rd 2024

Tailor-Made for a Lifelong Pursuit of Precision in Cancer Care

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Acute Myeloid Leukemia | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 20th 2024

Uproleselan Plus Chemo Fails to Improve OS in R/R AML in China

CP-CML | Image Credit: © สุพัฒตรา แสนพลี – stock.adobe.com
December 19th 2024

Olverembatinib Demonstrates Efficacy and Safety in Heavily Pretreated CP-CML